PYXS Overview

Preliminary Data Release: Pyxis Oncology announced preliminary results from Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma, showing a 46% overall response rate in monotherapy and 71% in combination with Keytruda, with high disease control rates.

Future Plans: The company plans to present updated data from both studies in mid and late 2026 and is evaluating the path forward for pivotal studies of MICVO as both a monotherapy and in combination with pembrolizumab.

Financial Update: Pyxis completed a sale of rights for $11 million to support MICVO development, but concerns over cash reserves and data interpretability led to a significant drop in share price, with analysts expressing caution regarding the trial's small sample size and tolerability issues.

Market Reaction: Following the data release, Pyxis shares fell approximately 49%, reflecting investor concerns about the limited interpretability of the results and the company's financial outlook, despite a slight recovery in premarket trading.

Analyst Upgrades: Truist Securities raised price targets for NXP Semiconductors and Tesla, maintaining a Buy and Hold rating respectively, while Wells Fargo upgraded Generac Holdings from Equal-Weight to Overweight.

Analyst Downgrades: Barclays downgraded Agco Corp from Equal-Weight to Underweight, cutting its price target significantly, while JP Morgan downgraded Lockheed Martin from Overweight to Neutral despite raising its price target.

Other Price Target Changes: Bernstein increased Caterpillar's price target while maintaining a Market Perform rating, and Piper Sandler raised Assurant's target with an Overweight rating.

Nike's Price Target Cut: Telsey Advisory Group reduced Nike's price target from $75 to $72, keeping a Market Perform rating as the stock closed lower.

U.S. Stock Market Performance: U.S. stocks saw gains, with the Nasdaq Composite rising over 200 points, while the Dow and S&P 500 also experienced increases. Consumer discretionary shares rose by 2%, but energy stocks fell by 0.5%.

Inflation and Economic Indicators: U.S. inflation cooled to 2.7% in November, below expectations, boosting investor confidence in the Federal Reserve's easing cycle. Initial jobless claims decreased to 224,000, and the Philadelphia Fed Manufacturing Index fell significantly.

Notable Stock Movements: Athira Pharma's shares surged 84% after a development agreement, while Trump Media & Technology Group and FuelCell Energy also saw significant gains. Conversely, Insmed Inc and Pyxis Oncology experienced sharp declines in their stock prices.

Global Market Trends: European shares rose, with the eurozone's STOXX 600 gaining 0.56%, while Asian markets closed mixed, with Japan's Nikkei falling and China's Shanghai Composite rising slightly.

U.S. Stock Market Performance: U.S. stocks rose significantly, with the Dow Jones gaining approximately 400 points, while the NASDAQ and S&P 500 also saw notable increases.

Accenture's Strong Earnings: Accenture reported better-than-expected first-quarter results for 2026, with earnings of $3.94 per share and sales of $18.7 billion, surpassing analyst estimates.

Equities Movement: Athira Pharma's shares surged 88% following an acquisition announcement, while Mega Fortune Co Ltd and Pyxis Oncology saw significant declines of 59% and 54%, respectively.

Economic Indicators: The Philadelphia Fed Manufacturing Index fell sharply, initial jobless claims decreased, and the annual inflation rate dropped to 2.7%, the lowest since July.